US Stock Market Move | Bambusa Therapeutics (BBTX.US) debuts on the U.S. stock market, shares fall over 8%.
As of press time, the stock fell over 8% to $14.685.
On Friday, Bambusa Therapeutics (BBTX.US) debuted on the U.S. stock market. As of press time, the stock fell over 8% to $14.685. The IPO price was $16. Bambusa Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, USA, focused on developing next-generation long-acting bispecific antibody drugs for the treatment of immune system and inflammatory diseases. These drugs can simultaneously target two disease-related biological targets, aiming to improve therapeutic efficacy, extend duration of action, and reduce patient dosing frequency. The company's lead investigational drug BBT001 is for the treatment of atopic dermatitis (eczema), chronic spontaneous urticaria, and other skin diseases; another candidate drug BBT002 primarily targets inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and chronic rhinosinusitis with nasal polyps. In addition, the company is developing early-stage drugs for inflammatory bowel disease and autoimmune diseases.
Related Articles
US Stock Market Move | Clinical-stage biotechnology company Aspen Neuroscience (ASPE.US) debuts on the U.S. stock market, with shares falling more than 17% after the opening.
The tech stock sell-off does not mean the end of the bull market. Wall Street strategists: fundamentals remain strong, and a pullback may be a buying opportunity.
US Stock Market Move | Crypto-related stocks weaken; Strategy (MSTR.US) falls over 6%.
US Stock Market Move | Clinical-stage biotechnology company Aspen Neuroscience (ASPE.US) debuts on the U.S. stock market, with shares falling more than 17% after the opening.
The tech stock sell-off does not mean the end of the bull market. Wall Street strategists: fundamentals remain strong, and a pullback may be a buying opportunity.
US Stock Market Move | Crypto-related stocks weaken; Strategy (MSTR.US) falls over 6%.
